Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05369221
Other study ID # RN-CT-001-1
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date April 25, 2022
Est. completion date October 10, 2023

Study information

Verified date October 2023
Source Peking Union Medical College Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In this study, 5 subjects will be enrolled and the cumulative D2cc dose for rectum during brachytherapy will be recorded as the primary outcome measures.


Description:

This is a phase I prospective study of 5 patients to determine if PEG hydrogel (ReSpace™) reduces the radiation dose delivered to the rectum during radiation therapy for cervical cancer by increasing the space between the cervix and the anterior rectal wall. In the other word, the purpose of this study is to assess whether the use of ReSpace™ hydrogel results in a reduction of radiation exposure to the anterior rectum.


Recruitment information / eligibility

Status Completed
Enrollment 8
Est. completion date October 10, 2023
Est. primary completion date October 10, 2023
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Patients with pathologically confirmed cervical cancer who must be scheduled to undergo radical radiotherapy by means of intensity-modulated radiotherapy combined with 3D brachytherapy. - Karnofsky score = 70. - Subjects aged = 18 years and = 75 years. - Subjects must be able to cooperate in completing the entire study. - The subjects' pelvic and abdominal cavity and joints are free of metal implants and can tolerate MRI. - No contraindications to CT scanning. - Subjects must be able to understand the purpose of the trial, voluntarily participate and sign an informed consent form. Exclusion Criteria: - Subjects who have received prior pelvic radiotherapy. - Subjects whose target tumors have been previously treated (chemotherapy, immunotherapy, surgical treatment, etc.) - Subjects with other primary malignancies - Subjects with contraindications to radiotherapy, as determined by the investigators - Subjects with injection site infections. - Subjects who are allergic to the ingredients of the device. - Subjects whose tumors invade the injection site and affect the injection process and injection safety, as determined by the investigators - Persons with severe mental illness, cognitive impairment and thinking disorders. - Participants in other drug clinical trials or medical device clinical trials 1 month prior to screening - Pregnant or lactating women or those who plan to get pregnant within the last six months - Subjects who cannot be followed up as prescribed by the doctor - Other conditions that, in the judgment of the investigator, make the subject unsuitable for enrollment

Study Design


Related Conditions & MeSH terms


Intervention

Device:
ReSpace™
All of the subjects will be injected with ReSpace™ hydrogel.

Locations

Country Name City State
China Peking Union Medical College Hospital Beijing

Sponsors (2)

Lead Sponsor Collaborator
Peking Union Medical College Hospital Shanghai Reunion Biotech Co.,Ltd.

Country where clinical trial is conducted

China, 

References & Publications (3)

de Freitas AC, Gurgel AP, Chagas BS, Coimbra EC, do Amaral CM. Susceptibility to cervical cancer: an overview. Gynecol Oncol. 2012 Aug;126(2):304-11. doi: 10.1016/j.ygyno.2012.03.047. Epub 2012 Apr 4. — View Citation

Kashihara T, Murakami N, Tselis N, Kobayashi K, Tsuchida K, Shima S, Masui K, Yoshida K, Takahashi K, Inaba K, Umezawa R, Igaki H, Ito Y, Kato T, Uno T, Itami J. Hyaluronate gel injection for rectum dose reduction in gynecologic high-dose-rate brachytherapy: initial Japanese experience. J Radiat Res. 2019 Jul 1;60(4):501-508. doi: 10.1093/jrr/rrz016. — View Citation

Peach MS, Moore J, Giles W, Trainor J, Long T, Moon N, Hylton JE, Showalter TN, Libby B. Development and preclinical testing of a novel biodegradable hydrogel vaginal packing technology for gynecologic high-dose-rate brachytherapy. J Contemp Brachytherapy. 2018 Aug;10(4):306-314. doi: 10.5114/jcb.2018.77952. Epub 2018 Aug 31. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary The cumulative D2cc dose for rectum during brachytherapy The mean of the cumulative rectum D2cc dose during brachytherapy will be calculated for subjects. which will be used to validate the parameter selection for phase II sample size estimation. 21 days post index procedure
Secondary Implantation success rate of hydrogel spacer The success rate of hydrogel spacer implantation will be evaluated by the investigator for subjects. during procedure
Secondary Evaluation of device performance of hydrogel spacer The ease of use of the test device will be evaluated by the investigator on the day of Operation. The evaluation items are as follows:
Whether the device is easy to assemble.
Whether the process of positioning the needle is smooth and whether it is easy to position the needle.
Whether the device is easy to inject and whether the injection process is smooth.
during procedure
Secondary Injection volume of hydrogel spacer Recording the amount of hydrogel spacer injected in the subjects,which will be used to evaluate the reasonableness of the injected dose of ReSpace™ when hydrogel is injected between the rectum and cervix in women undergoing radiation therapy. during procedure
See also
  Status Clinical Trial Phase
Not yet recruiting NCT03225443 - Observation and Evaluation of Short-term Curative Effect of Local Advanced Cervical Cancer Treated With Particle Radiotherapy Versus Neoadjuvant Chemotherapy N/A
Recruiting NCT01373723 - Economic Evaluation of Three Populational Screening Strategies for Cervical Cancer N/A
Terminated NCT01234480 - Intended Use Study of the BD SurePath Plus™ Pap
Terminated NCT01194609 - A Pilot Study of Radiation-Immune Cell Combination Therapy in Cervical Cancer Phase 1/Phase 2
Completed NCT02808832 - An HPV Vaccine Provider Intervention in Safety Net Clinics N/A
Completed NCT01014026 - Self-sampling and Human Papillomavirus (HPV)-Testing for Unscreened Women in Cervical Cancer Prevention Phase 3
Terminated NCT01075412 - FLT PET Imaging for Cervical Cancer Phase 2
Completed NCT02865889 - Cost-Effectiveness and Patients Satisfaction of Conventional vs Robotic-Assisted Laparoscopy in Gynecologic Oncologic Indications N/A
Completed NCT00377845 - Cervix Cytological Screening - Comparison of Tampon Self-Test and the Routine Smear. Phase 0
Recruiting NCT05531981 - Detection of Minimal Residual Disease Based on HPV ctDNA in Cervical Cancer
Recruiting NCT05393440 - First-in-human (FIH) Phase I Trial of BS-006 in Cervical Cancer Phase 1
Recruiting NCT05007106 - MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) Phase 2
Completed NCT02866006 - Safety and Tolerability Evaluation Study of BVAC-C in Patients With HPV Type 16 or 18 Positive Cervical Cancer Phase 1/Phase 2
Completed NCT03270995 - Cognitive-Existential Group Therapy to Reduce Fear of Cancer Recurrence: A RCT Study N/A
Completed NCT02320578 - 2D Versus 3D Radical Laparoscopic Hysterectomy for Cervical Cancer: a Prospective Randomized Trial N/A
Terminated NCT02900248 - CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice
Not yet recruiting NCT05065853 - Urinary and Vaginal HPV Testing in Cervical Cancer Screening
Completed NCT01231945 - Low-Cost Molecular Cervical Cancer Screening Study N/A
Completed NCT01717391 - [F-18] Fluorothymidine PET/CT Imaging for Pelvic Cancers Phase 2
Active, not recruiting NCT04947605 - Epidemiological Landscape of Cervical Cancer in Latin America